Secondly, the most recent clinical trials suggest that early intervention and pharmacological options, such as GLP1-RAs, are vital for limiting NAFLD progression to severe NASH, NASF, and cirrhosis, in addition to off-label use in case reports indicating their success even in progressive NASH with developed cirrhosis. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.